Current Clinical Trial News and Events

Current Clinical Trial News and Events, Clinical Trial News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Trying to beat a coke habit with cannabis? Not so fast !
Taking cannabidiol, a chemical in the cannabis sativa plant, isn't an effective way to reduce your dependence on cocaine, researchers at the CHUM Research Centre find. (2021-01-27)

In preclinical models, antiviral better inhibits COVID-19 than Remdesivir; further studies warranted
Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. (2021-01-25)

New maintenance treatment for acute myeloid leukemia prolongs the lives of patients
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. (2021-01-22)

Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients
A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn't live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in JAMA Oncology. (2021-01-21)

Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients
Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology. (2021-01-21)

Gastrointestinal surgery can be a cure for type 2 diabetes finds new long-term study
The results of a randomised clinical trial with the longest follow up to date show that metabolic surgery is more effective than medications and lifestyle interventions in the long-term control of severe type 2 diabetes. (2021-01-21)

New trial finds arthritis drug no better than standard care for severe covid-19
Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds a new trial published by The BMJ today. (2021-01-20)

Target of new cancer treatment valid for breast as well as blood cancers: study
Newly published research shows that a new anti-cancer drug developed at the University of Alberta, set to begin human trials this year, may work against breast cancer as well as blood cancer. (2021-01-20)

Benvitimod cream: a new topical treatment for plaque psoriasis
Psoriasis is a chronic inflammatory skin condition characterized by skin plaques and itching. Currently, the most common topical treatments for psoriasis are corticosteroids and vitamin D3 analogs. But these drugs have various side-effects. A recent phase III clinical trial of the novel non-steroidal compound benvitimod in China, published in Chinese Medical Journal, shows that it is safe and effective and could be a promising new topical treatment for psoriasis. (2021-01-19)

Study demonstrates efficacy of new treatment for neurofibromatosis type 1-related tumors
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1). The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine. (2021-01-14)

Scientists reveal mechanism that causes irritable bowel syndrome
KU Leuven researchers have identified the biological mechanism that explains why some people experience abdominal pain when they eat certain foods. The finding paves the way for more efficient treatment of irritable bowel syndrome and other food intolerances. The study, carried out in mice and humans, was published in Nature. (2021-01-13)

Hope for children with rare heart condition: novel stem cell therapy to save the day
In a new study, scientists at Okayama University isolated cardiac stem cells and assessed their potential use as regenerative therapy in young patients with cardiac defects. They confirmed the safety and effectiveness of their proposed treatment in early-phase trials and even identified the mechanism through which the stem cells improved cardiac function. Based on these preliminary findings, they hope to proceed to larger clinical trials and move towards pharmaceutical approval in the future. (2021-01-12)

Tapping the brain to boost stroke rehabilitation
Stroke survivors who had ceased to benefit from conventional rehabilitation gained clinically significant arm movement and control by using an external robotic device powered by the patients' own brains. (2021-01-12)

Consent forms design influences patient willingness to share personal health information
Patients are sometimes asked to share their personal health information for research purposes. Informed consent and trust are critical components in a patient's decision to participate in research. Researchers at the University of Florida conducted a three-arm randomized controlled trial to compare the effects on patient experiences of three electronic consent (e-consent) designs that asked them to share PHI for research purposes. (2021-01-12)

New tech helping cancer patients manage symptoms
Hundreds of cancer patients have benefitted from using computer algorithms to manage their symptoms and improve their wellbeing in a unique UK trial by the University of Leeds. Patients tested the eRAPID system which allowed them to report online symptoms from home and receive instant advice on whether to self-manage or seek medical attention. (2021-01-08)

Beating the bulge with a nice cup of tea
Researchers led by the University of Tsukuba found that healthy volunteers who consumed oolong tea every day had much higher levels of fat breakdown compared with the placebo group, and that the effects were most noticeable during sleep. Importantly, the volunteers developed a tolerance to caffeine over the 2-week study period, with their sleep patterns remaining unaffected by tea or caffeine consumption, indicating that oolong tea may have clinical relevance for weight control. (2021-01-06)

Retracted scientific paper persists in new citations, study finds
University of Illinois information sciences professor Jodi Schneider is leading an effort to prevent the spread of retracted research. (2021-01-05)

Peer-reviewed report on Moderna COVID-19 vaccine publishes
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD). (2020-12-30)

Global trial reveals life saving drug for acute myeloid leukemia
Results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML), significantly improving survival in older patients, over the age of 55, with the disease. AML is the most acute blood cancer in adults and its incidence increases with age, with a poor prognosis. (2020-12-23)

Liquid bandage detects tissue oxygenation without the drawbacks of wired oximeters
A paint-on, transparent bandage containing phosphorescent materials reads the amount of oxygen reaching transplanted tissue -- a critical component of a transplant's success. Existing oximeter technology is complicated to use, restricts patients' movements, and is subject to false alarms. The first human trial of the liquid bandage in women undergoing breast reconstruction after cancer found that it performed as well as a wired oximeter device, the current clinical standard. (2020-12-22)

Results of NIH-sponsored ACTIV-3 trial published
Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in NEJM. The antibody did not provide clinical benefit compared to placebo. The trial, which had been halted to new enrollment in late October following a recommendation by the independent Data and Safety Monitoring Board (DSMB), is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. NIAID sponsored the trial. (2020-12-22)

Sex-specific Alzheimer's treatment could benefit males over females
A University of Ottawa study found a specific Alzheimer's treatment is effective in male and not female mice, providing a window into the biology of the disease and the effectiveness of targeted treatments. (2020-12-21)

Additional analyses of pridopidine for HD
Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in peer-reviewed journal, The Journal of Huntington's Disease. Exploratory additional efficacy data show pridopidine (45 mg bid) to be first drug to exert a significant and clinically meaningful beneficial effect on Total Functional Capacity. Results from Open-HART trial demonstrate potential durability of effect of pridopidine with less TFC decline over 5 years compared to historical placebo group, as well as positive safety and tolerability data. (2020-12-16)

CAN risk in diabetes reduced with intensive control of blood glucose and blood pressure
Cardiovascular autonomic neuropathy (CAN), a frequent but underdiagnosed complication of diabetes that can be life-threatening. Researchers found that intensive glycemic control reduced CAN risk by 17%, while intensive blood pressure control reduced risks by 22%. (2020-12-16)

Clowns may help children cope with the pain and anxiety of hospital treatment
Hospital clowns might help improve physical symptoms and psychological wellbeing in children and adolescents having treatment for acute or chronic conditions, finds a study in the Christmas issue of The BMJ. (2020-12-16)

COVID-19 preprint data rapidly influenced critical care practice
In a new research letter published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine, researchers examine whether preprint data on the use of the corticosteroid dexamethasone influenced clinical practice in treating COVID-19 critical care patients throughout Australia. (2020-12-15)

Point of Care testing can improve the detection and treatment of influenza
Southampton-led research has shown that implementing point-of-care testing in hospitals to diagnose influenza can lead to better treatment and faster recovery for patients. The researchers are now calling for routine use of these tests to become standard for patients admitted with acute respiratory symptoms during the influenza season. (2020-12-14)

Higher variability in glomerular filtration rate is associated with higher mortality
In this paper published in the American Journal of Kidney Diseases (AJKD), researchers evaluated associations between eGFR variability and subsequent cardiovascular disease (CVD) events and all-cause mortality among SPRINT participants. They found that greater eGFR variability was associated with higher risk of all-cause mortality independent of baseline eGFR, albuminuria, and other risk factors. (2020-12-14)

From publication bias to lost in information
From publication bias to lost in information In BMJ Evidence-Based Medicine, IQWiG researchers call for a central, public and worldwide portal for clinical trials (2020-12-11)

Baricitinib plus Remdesivir shows promise for treating COVID-19
The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in The New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. (2020-12-11)

Immunotherapy improves responses w/o reducing quality of life in early breast cancer
Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows. (2020-12-10)

Testing memory over four weeks could predict Alzheimer's disease risk
New research suggests testing people's memory over four weeks could identify who is at higher risk of developing Alzheimer's disease before it has developed. Importantly, the trial found testing people's ability to retain memories for longer time periods could predict this more accurately than classic memory tests, which test memory over half an hour. (2020-12-10)

The immunomodulatory activity of a drug would improve the efficacy of immunotherapy in breast cancer
* The team of Eva González-Suarez, from the CNIO and IDIBELL, and the team of Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumours * These findings propose a new target to increase the antitumor immune response and make breast cancer more sensitive to immunotherapy (2020-12-10)

Phase 1 trial assesses whether fecal microbiota transplant impacts cancer patients resistant to immu
In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes. (2020-12-10)

New treatment could spare early-stage rectal cancer patients life-altering side effects
A new and less invasive treatment developed by Cancer Research UK researchers is safer than standard major surgery for early-stage rectal cancer, giving patients a better quality of life with fewer life-altering side effects, results from a pilot study show. (2020-12-10)

Some postmenopausal women with common breast cancer may forgo chemotherapy
Postmenopausal women with a common form of breast cancer may safely skip chemotherapy, according to study results from SWOG Cancer Research Network, funded by the National Cancer Institute, to be released at the San Antonio Breast Cancer Symposium. (2020-12-09)

First peer-reviewed results of phase 3 human trials of Oxford vaccine show efficacy
Wits University scientists were amongst the co-authors who published the first peer-reviewed results of phase 3 human trials of the Oxford/AstraZeneca Covid-19 vaccine, in prestigious scientific journal The Lancet, on 8 December. Wits leads the SA leg of the Oxford Covid-19 vaccine trials. (2020-12-09)

UL, Ireland, research finds promising treatment to protect kidney function in diabetes
A clinical trial involving researchers at University of Limerick, Ireland has demonstrated the potential benefits of new drugs in protecting kidney function in diabetes. (2020-12-09)

Single-eye gene therapy improves vision in both eyes of patients with inherited eye disorder
A gene therapy for an inherited eye disorder can ameliorate vision loss in both eyes despite only being injected into one, according to a phase 3 clinical trial involving 37 patients. (2020-12-09)

CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments. (2020-12-06)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.